Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2023-11-24 Annual Report
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the company 'iNtRON Biotechnology' for the fiscal year 2022. It contains detailed financial information, management discussion, business operations, and governance details. It is a comprehensive annual filing submitted to the Korean financial authorities (Financial Supervisory Service/KRX). Based on the content and structure, it is classified as an Annual Report (10-K). FY 2022
2023-11-24 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'iNtRON Biotechnology' covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial information, business descriptions, and management disclosures required by the Korean Financial Supervisory Service (FSS) and the Korea Exchange. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. 9M 2023
2023-11-14 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from Intron Biotechnology regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). This type of filing details the company's repurchase or redemption of its own debt instruments (convertible bonds) before the scheduled maturity date. This falls under the category of capital structure changes and financing updates, specifically related to debt management. Given the specific nature of the filing regarding the company's capital structure and debt obligations, 'CAP' (Capital/Financing Update) is the most accurate classification.
2023-09-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock pledge contracts) of major shareholders and special related parties of Intron Biotechnology. This type of filing is specifically categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2023-08-11 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is titled '반기보고서' (Semi-annual Report) for the company 'iNtRON Biotechnology' covering the period from 2023-01-01 to 2023-06-30. It contains detailed financial information, business operations, and management discussions, which is characteristic of an interim/quarterly report in the Korean regulatory filing system (DART). H1 2023
2023-08-11 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean financial authorities regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This falls under the category of corporate actions related to share buybacks or treasury share management. Since the document details the specific decision to terminate a share repurchase trust and the subsequent handling of those shares, it is classified as a transaction in own shares.
2023-08-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.